Philippines Breast Cancer Therapeutics Market Analysis Report 2022 to 2030

Philippines Breast Cancer Therapeutics Market Analysis

$ 3999

The Philippines' breast cancer therapeutics market is expected to witness growth from $40 Mn in 2022 to $xx Mn in 2030 with a CAGR of xx% for the year 2022-30. The market drivers for the Philippines breast cancer therapeutics market are the increasing prevalence of breast cancer and the introduction of novel therapeutics. The market is segmented by therapy, by cancer type, and by distribution channel. Major companies leading the market are AstraZeneca, Otsuka Pharmaceutical Co., Ltd., and Syndax.

ID: IN10PHPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Phillipines AUTHOR: Parul Choudhary

Buy Now

Philippines Breast Cancer Therapeutics Market Executive Analysis

The Philippines' breast cancer therapeutics market size is at around $40 Mn in 2022 and is projected to reach $xx Mn in 2030, exhibiting a CAGR of xx% during the forecast period. The proposed $280 Bn national budget for 2023 was presented to Congress by the Philippines Department of Budget and Management (DBM), and it includes $296.3 Bn for the health sector. The DBM emphasized that the $15.67 Bn proposed budget for the health sector is 10.4% larger than this year's budget in order to improve the healthcare system, particularly in light of the persistent challenges posed by infectious illnesses. $1.53 Bn has been set aside for the purchase of drugs and vaccinations, while $1 Bn has been set aside for the pay and benefits of healthcare personnel.

Breast cancer accounts for 25% of all cancer diagnoses in the Philippines, making it the most prevalent type of cancer in women. In fact, the most recent study from the Philippine Cancer Society reported 20,267 new instances of breast cancer in 2015 and, more concerningly, an estimated 7,384 breast cancer fatalities in the same year. The age-standardized rate (ASR) for breast cancer in Filipino women is 47 per 100,000 women, which means that 1 out of every 13 Filipino women is predicted to develop the disease in her lifetime, according to the International Agency for Research on Cancer (IARC).

Only 2% to 3% of breast cancer cases in the Philippines were discovered at Stage I, whereas 53% of cases were found to be in Stages III and IV. These results are especially troubling because advancements in breast cancer survival rates are supported by prompt and efficient treatments made possible by early detection and screening. The Philippines currently lacks a widespread breast cancer screening program. The Philippines Breast Cancer Control Program (BCCP) places a strong emphasis on the value of both monthly Breast Self-Examination (BSE) and annual Clinical Breast Examination (CBE) from medical specialists. For malignancies that may be treated, public awareness campaigns regarding the warning signs and symptoms of the disease as well as modifications to the health care system to promote early detection and rapid cancer diagnosis may be practical and affordable cancer control measures.

philippines breast cancer therapeutics market analysis

Market Dynamics

Market Growth Drivers

The Philippines market for breast cancer therapeutics will expand as breast cancer cases become more common and the female population rises. The expansion of the breast cancer therapeutics market will also be supported by growing research and development capabilities in the Philippines to bring novel pharmaceutical drugs and innovate with breast cancer treatment technology. Increased public knowledge of potential surgical choices and treatment modalities will help the breast cancer therapeutics market in the Philippines expand at a faster rate.

Market Restraints

The high expense of receiving surgical care will put a barrier in the way of breast cancer therapeutics market expansion in the Philippines. Therapeutic side effects will once more pose a threat to the market expansion. The market growth rate will further be hampered by the poor technology infrastructure in the Philippines.

Competitive Landscape

Key Players

Getz Pharma (PHL)
Ferring (PHL)
AstraZeneca (PHL)
Otsuka Pharmaceutical (PHL)
Syndax
Merck
BioMarin

Healthcare Policies and Regulatory Landscape

Breast cancer is regarded as a PhilHealth-covered sickness in the Philippines, which entitles those with PhilHealth coverage to reimbursement for some costs associated with breast cancer. Both diagnostic procedures like mammography, ultrasound, and biopsies as well as therapeutic alternatives like surgery, chemotherapy, and radiation therapy are covered by PhilHealth. Through its "Lingkod Bayan Breast Cancer Screening Program," which is run in collaboration with local government agencies and business partners, the Department of Health (DOH) additionally offers free breast cancer screening services. The program aims to improve underprivileged and high-risk groups' access to breast cancer screening services in the Philippines. The "Pink Card" program, run by the government, offers underprivileged people financial aid for breast cancer treatment. The Philippine Charity Sweepstakes Office (PCSO) and the DOH are responsible for putting the scheme into action.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.